

# David A Henry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8586131/publications.pdf>

Version: 2024-02-01

305  
papers

38,651  
citations

19608

61  
h-index

3257

185  
g-index

315  
all docs

315  
docs citations

315  
times ranked

42116  
citing authors

#	ARTICLE	IF	CITATIONS
1	ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. <i>BMJ</i> , The, 2016, 355, i4919.	3.0	8,654
2	Grading quality of evidence and strength of recommendations. <i>BMJ: British Medical Journal</i> , 2004, 328, 1490.	2.4	6,376
3	AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. <i>BMJ: British Medical Journal</i> , 2017, 358, j4008.	2.4	4,681
4	AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1013-1020.	2.4	1,427
5	Cardiovascular Risk and Inhibition of Cyclooxygenase. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1633.	3.8	966
6	Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. <i>BMC Health Services Research</i> , 2004, 4, 38.	0.9	883
7	Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. <i>BMJ: British Medical Journal</i> , 1996, 312, 1563-1566.	2.4	680
8	Selling sickness: the pharmaceutical industry and disease mongering * Commentary: Medicalisation of risk factors. <i>BMJ: British Medical Journal</i> , 2002, 324, 886-891.	2.4	676
9	A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. <i>Cmaj</i> , 2009, 180, 713-718.	0.9	622
10	Preventing overdiagnosis: how to stop harming the healthy. <i>BMJ</i> , The, 2012, 344, e3502-e3502.	3.0	512
11	Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. <i>PLoS Medicine</i> , 2011, 8, e1001098.	3.9	449
12	Coverage by the News Media of the Benefits and Risks of Medications. <i>New England Journal of Medicine</i> , 2000, 342, 1645-1650.	13.9	448
13	Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients. <i>Archives of Internal Medicine</i> , 2000, 160, 777.	4.3	410
14	Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2011, , CD001886.		372
15	V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women. <i>Endocrine Reviews</i> , 2002, 23, 529-539.	8.9	329
16	Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries. <i>PLoS Medicine</i> , 2013, 10, e1001388.	3.9	288
17	Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. <i>Gastroenterology</i> , 1993, 105, 1078-1088.	0.6	276
18	Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. <i>BMJ: British Medical Journal</i> , 1995, 310, 897-901.	2.4	272

#	ARTICLE	IF	CITATIONS
19	Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2011, , CD001886.		258
20	Transfusion triggers: A systematic review of the literature*. Transfusion Medicine Reviews, 2002, 16, 187-199.	0.9	244
21	Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 395, 1927-1936.	6.3	224
22	A 3-year study of high-cost users of health care. Cmaj, 2016, 188, 182-188.	0.9	206
23	Problems With the Interpretation of Pharmacoeconomic Analyses. JAMA - Journal of the American Medical Association, 2000, 283, 2116.	3.8	190
24	Cell salvage for minimising perioperative allogeneic blood transfusion. , 2010, , CD001888.		180
25	The Fight against Disease Mongering: Generating Knowledge for Action. PLoS Medicine, 2006, 3, e191.	3.9	175
26	Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2007, , CD001886.		175
27	Improved Outcomes With Early Collaborative Care of Ambulatory Heart Failure Patients Discharged From the Emergency Department. Circulation, 2010, 122, 1806-1814.	1.6	159
28	Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism.. BMJ: British Medical Journal, 1980, 281, 775-777.	2.4	153
29	Cimetidine and Tranexamic Acid in the Treatment of Acute Upper-Gastrointestinal-Tract Bleeding. New England Journal of Medicine, 1983, 308, 1571-1575.	13.9	152
30	The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. Cmaj, 2009, 180, 183-193.	0.9	151
31	Cell salvage for minimising perioperative allogeneic blood transfusion. , 2010, , CD001888.		151
32	Autologous transfusion techniques: a systematic review of their efficacy. Transfusion Medicine, 2004, 14, 123-144.	0.5	149
33	Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. British Journal of Surgery, 2006, 93, 810-819.	0.1	144
34	The pharmaceutical industry as a medicines provider. Lancet, The, 2002, 360, 1590-1595.	6.3	133
35	Describing treatment effects to patients. Journal of General Internal Medicine, 2003, 18, 948-959.	1.3	129
36	Benzodiazepine Use as a Cause of Cognitive Impairment in Elderly Hospital Inpatients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1995, 50A, M99-M106.	1.7	128

#	ARTICLE	IF	CITATIONS
37	A Quality Use of Medicines program for general practitioners and older people: a cluster randomised controlled trial. Medical Journal of Australia, 2007, 187, 23-30.	0.8	122
38	Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes, Obesity and Metabolism, 2002, 4, 201-208.	2.2	121
39	What Are the Roles and Responsibilities of the Media in Disseminating Health Information?. PLoS Medicine, 2005, 2, e215.	3.9	121
40	Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion. The Cochrane Library, 2001, , CD003602.	1.5	117
41	The effects of information framing on the practices of physicians. Journal of General Internal Medicine, 1999, 14, 633-642.	1.3	112
42	Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia. BMJ: British Medical Journal, 1999, 318, 507-511.	2.4	111
43	Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Medical Journal of Australia, 1989, 150, 329-331.	0.8	110
44	Economic Analysis as an Aid to Subsidisation Decisions. Pharmacoeconomics, 1992, 1, 54-67.	1.7	109
45	Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids.. BMJ: British Medical Journal, 1987, 295, 1227-1229.	2.4	108
46	Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet, The, 1994, 343, 159-162.	6.3	108
47	Parenteral aluminum administration in the dog: II. Induction of osteomalacia and effect on vitamin D metabolism. Kidney International, 1984, 25, 370-375.	2.6	107
48	The effects of increased rehabilitation therapy after brain injury: results of a prospective controlled trial. Clinical Rehabilitation, 2001, 15, 501-514.	1.0	107
49	Cohort Profile: The Hunter Community Study. International Journal of Epidemiology, 2010, 39, 1452-1463.	0.9	106
50	Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. , 2010, , CD002042.		100
51	The efficiency frontier approach to economic evaluation of health care interventions. Health Economics (United Kingdom), 2010, 19, 1117-1127.	0.8	97
52	Drug Prices and Value for Money. JAMA - Journal of the American Medical Association, 2005, 294, 2630.	3.8	94
53	Evaluation of a Weight-Adjusted Single-Bolus Plasminogen Activator in Patients With Myocardial Infarction. Circulation, 1998, 98, 2117-2125.	1.6	92
54	Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. British Journal of Clinical Pharmacology, 1997, 44, 85-90.	1.1	90

#	ARTICLE	IF	CITATIONS
55	Development of an Active Fault-Tolerant Flight Control Strategy. <i>Journal of Guidance, Control, and Dynamics</i> , 2008, 31, 135-147.	1.6	89
56	Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. <i>British Journal of Surgery</i> , 2002, 89, 695-703.	0.1	88
57	Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. <i>JAMA Internal Medicine</i> , 2016, 176, 1464.	2.6	87
58	Development of Hematopoietic Cancers After Implantation of Total Joint Replacement. <i>Clinical Orthopaedics and Related Research</i> , 1996, 329, S290-S296.	0.7	85
59	SOMATOSTATIN IN TREATMENT OF HAEMATEMESIS AND MELAENA. <i>Lancet, The</i> , 1985, 325, 130-132.	6.3	80
60	Media Reporting of Health Interventions: Signs of Improvement, but Major Problems Persist. <i>PLoS ONE</i> , 2009, 4, e4831.	1.1	80
61	Monitoring the quality of medical news reporting: early experience with media doctor. <i>Medical Journal of Australia</i> , 2005, 183, 190-193.	0.8	77
62	Parenteral aluminum administration in the dog: I. Plasma kinetics, tissue levels, calcium metabolism, and parathyroid hormone. <i>Kidney International</i> , 1984, 25, 362-369.	2.6	75
63	Using Evidence to Combat Overdiagnosis and Overtreatment: Evaluating Treatments, Tests, and Disease Definitions in the Time of Too Much. <i>PLoS Medicine</i> , 2014, 11, e1001655.	3.9	75
64	Short-Term Treatment with Zanamivir to Prevent Influenza: Results of a Placebo-Controlled Study. <i>Clinical Infectious Diseases</i> , 2000, 30, 587-589.	2.9	74
65	Diclofenac hepatitis.. <i>Gut</i> , 1991, 32, 1381-1385.	6.1	69
66	WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys. <i>PLoS Medicine</i> , 2014, 11, e1001724.	3.9	68
67	Cholestatic Hepatitis Associated with Flucloxacillin. <i>Medical Journal of Australia</i> , 1993, 158, 596-600.	0.8	66
68	Cell salvage for minimising perioperative allogeneic blood transfusion. , 2006, , CD001888.		65
69	The health services burden of heart failure: an analysis using linked population health data-sets. <i>BMC Health Services Research</i> , 2012, 12, 103.	0.9	63
70	Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. <i>The Cochrane Library</i> , 2003, , CD004171.	1.5	62
71	Hyponatraemia during carbamazepine treatment.. <i>BMJ: British Medical Journal</i> , 1977, 1, 83-84.	2.4	60
72	Side-effects of non-steroidal anti-inflammatory drugs. <i>Bailliere's Clinical Rheumatology</i> , 1988, 2, 425-454.	1.0	59

#	ARTICLE	IF	CITATIONS
73	Pharmaceuticals, intellectual property and free trade: the case of the US–Australia free trade agreement. <i>Prometheus</i> , 2004, 22, 243-257.	0.2	59
74	Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 368-375.	2.2	58
75	Erythromycin–Associated Cholestatic Hepatitis. <i>Medical Journal of Australia</i> , 1993, 158, 600-602.	0.8	57
76	Indigenous health data and the path to healing. <i>Lancet, The</i> , 2017, 390, 2022-2023.	6.3	57
77	Assessment of Long-term Follow-up of Randomized Trial Participants by Linkage to Routinely Collected Data. <i>JAMA Network Open</i> , 2018, 1, e186019.	2.8	56
78	Effectiveness of COVID–19 vaccines: findings from real world studies. <i>Medical Journal of Australia</i> , 2021, 215, 149.	0.8	56
79	Cimetidine and ranitidine in duodenal ulcer.. <i>BMJ: British Medical Journal</i> , 1980, 281, 473-474.	2.4	55
80	Propranolol steady-state pharmacokinetics are unaltered by omeprazole. <i>European Journal of Clinical Pharmacology</i> , 1987, 33, 369-373.	0.8	55
81	Current Problems with Non-Specific COX Inhibitors. <i>Current Pharmaceutical Design</i> , 2000, 6, 1693-1724.	0.9	54
82	Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. <i>BMC Cardiovascular Disorders</i> , 2005, 5, 19.	0.7	54
83	Increasing the demand for childhood vaccination in developing countries: a systematic review. <i>BMC International Health and Human Rights</i> , 2009, 9, S5.	2.5	54
84	The Impact of WHO Essential Medicines Policies on Inappropriate Use of Antibiotics. <i>PLoS ONE</i> , 2016, 11, e0152020.	1.1	54
85	CNODES: the Canadian Network for Observational Drug Effect Studies. <i>Open Medicine</i> , 2012, 6, e134-40.	1.5	52
86	An Analysis of News Media Coverage of Complementary and Alternative Medicine. <i>PLoS ONE</i> , 2008, 3, e2406.	1.1	51
87	A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects. <i>Climacteric</i> , 1998, 1, 112-123.	1.1	50
88	Omeprazole: effects on oxidative drug metabolism.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 195-200.	1.1	49
89	Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. , 2000, , CD002042.		49
90	Lesson From Canada’s Universal Care: Socially Disadvantaged Patients Use More Health Services, Still Have Poorer Health. <i>Health Affairs</i> , 2011, 30, 274-283.	2.5	49

#	ARTICLE	IF	CITATIONS
91	Sensor fault diagnosis using a non-homogeneous high-order sliding mode observer with application to a transport aircraft. IET Control Theory and Applications, 2015, 9, 598-607.	1.2	48
92	Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool. PLoS Medicine, 2016, 13, e1001987.	3.9	47
93	Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. Cmaj, 2016, 188, 723-730.	0.9	47
94	TECHNOLOGIES TO MINIMIZE BLOOD TRANSFUSION IN CARDIAC AND ORTHOPEDIC SURGERY. International Journal of Technology Assessment in Health Care, 1999, 15, 717-728.	0.2	46
95	Disease Mongering Is Now Part of the Global Health Debate. PLoS Medicine, 2008, 5, e106.	3.9	46
96	Continuous infusion of frusemide in refractory oedema.. BMJ: British Medical Journal, 1978, 2, 476-476.	2.4	45
97	[14C]aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis. Digestive Diseases and Sciences, 1985, 30, 813-818.	1.1	45
98	Single-Enantiomer Drugs. Clinical Pharmacokinetics, 2004, 43, 287-290.	1.6	45
99	10. Meta-analysis: Part 2: assessing the quality of published meta-analyses. Medical Journal of Australia, 1992, 156, 173-187.	0.8	44
100	Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Medical Journal of Australia, 2005, 182, 557-560.	0.8	43
101	Drug use in Australia: a community prevalence study. Medical Journal of Australia, 1992, 156, 759-764.	0.8	41
102	Prescription Drug Utilization Following Patient Co-Payment Changes in Australia. , 1996, 5, 385-392.		41
103	Sex ratios among Canadian liveborn infants of mothers from different countries. Cmaj, 2012, 184, E492-E496.	0.9	41
104	Nonsteroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales. Gastroenterology, 1993, 104, 1083-1091.	0.6	40
105	Management and outcomes of congestive heart failure: a prospective study of hospitalised patients. Medical Journal of Australia, 1998, 168, 115-118.	0.8	40
106	Adverse reactions to frusemide in hospital inpatients.. BMJ: British Medical Journal, 1979, 2, 360-362.	2.4	39
107	Promoting cost effective prescribing. BMJ: British Medical Journal, 1995, 310, 955-956.	2.4	39
108	Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?. BMJ: British Medical Journal, 1977, 1, 691-692.	2.4	38

#	ARTICLE	IF	CITATIONS
109	Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. <i>Internal Medicine Journal</i> , 2006, 36, 571-578.	0.5	38
110	Supervisory fault-tolerant control with mutual performance optimization. <i>International Journal of Adaptive Control and Signal Processing</i> , 2013, 27, 251-279.	2.3	38
111	Socioeconomic gradients in all-cause, premature and avoidable mortality among immigrants and long-term residents using linked death records in Ontario, Canada. <i>Journal of Epidemiology and Community Health</i> , 2017, 71, 625-632.	2.0	38
112	Severe Hypokalemia in Hospitalized Patients. <i>Archives of Internal Medicine</i> , 1979, 139, 978.	4.3	36
113	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 840-851.	0.4	36
114	A Prompt to the Web: The Media and Health Information Seeking Behaviour. <i>PLoS ONE</i> , 2012, 7, e34314.	1.1	36
115	Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. <i>International Journal of Clinical Practice</i> , Supplement, 2003, , 43-9.	0.3	36
116	Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994 A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. <i>Medical Journal of Australia</i> , 1996, 164, 589-592.	0.8	35
117	Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 461-472.	1.1	35
118	Differential pricing of drugs: a role for cost-effectiveness analysis?. <i>Lancet</i> , The, 2002, 359, 2105-2107.	6.3	34
119	Comparing treatments. <i>BMJ: British Medical Journal</i> , 1995, 310, 1279-1279.	2.4	33
120	Cyclooxygenase-2 inhibitors and coronary occlusion - exploring dose-response relationships. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 358-365.	1.1	32
121	Coverage with evidence development: The Ontario experience. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 159-168.	0.2	32
122	Adverse Effects of Anti-ulcer Drugs. <i>Drugs</i> , 1981, 21, 444-459.	4.9	31
123	The impact of specialists on prescribing by general practitioners. <i>Medical Journal of Australia</i> , 2001, 175, 407-411.	0.8	31
124	Drug information for consumers: should it be disease or medication specific? Results of a community survey. <i>Australian and New Zealand Journal of Public Health</i> , 2001, 25, 564-570.	0.8	30
125	Sex ratios at birth after induced abortion. <i>Cmaj</i> , 2016, 188, E181-E190.	0.9	30
126	Accumulation Of Chronic Conditions At The Time Of Death Increased In Ontario From 1994 To 2013. <i>Health Affairs</i> , 2018, 37, 464-472.	2.5	30



#	ARTICLE	IF	CITATIONS
127	Moral hazard and prescription medicine use in Australia—the patient perspective. <i>Social Science and Medicine</i> , 2005, 60, 1437-1443.	1.8	29
128	Empirical uncertainty and moral contest: A qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia. <i>Social Science and Medicine</i> , 2006, 62, 1510-1519.	1.8	29
129	Evaluating medicines: let's use all the evidence. <i>Medical Journal of Australia</i> , 2007, 186, 249-252.	0.8	29
130	Does It Matter Who Writes Medical News Stories?. <i>PLoS Medicine</i> , 2010, 7, e1000323.	3.9	29
131	Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2013, 21, 50.	0.9	29
132	Plasma Noradrenaline, Platelet alpha2-Adrenoceptors, and Functional Scores during Ethanol Withdrawal. <i>Alcoholism: Clinical and Experimental Research</i> , 1990, 14, 497-502.	1.4	28
133	How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 3-7.	0.9	28
134	The [14C]aminopyrine breath test. A comparison of different forms of analysis.. <i>British Journal of Clinical Pharmacology</i> , 1979, 8, 539-545.	1.1	27
135	Disease mongering: expanding the boundaries of treatable disease. <i>Internal Medicine Journal</i> , 2008, 38, 858-861.	0.5	27
136	Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 927-934.	1.1	27
137	Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals. <i>PLoS Medicine</i> , 2009, 6, e1000128.	3.9	27
138	Effect of computerised prescribing on use of antibiotics. <i>Medical Journal of Australia</i> , 2003, 178, 210-213.	0.8	25
139	Patient co-payments and use of prescription medicines. <i>Australian and New Zealand Journal of Public Health</i> , 2004, 28, 62-67.	0.8	25
140	Selective COX-2 Inhibitors: A Promise Unfulfilled?. <i>Gastroenterology</i> , 2007, 132, 790-794.	0.6	25
141	Narrowing mortality gap between men and women over two decades: a registry-based study in Ontario, Canada. <i>BMJ Open</i> , 2016, 6, e012564.	0.8	25
142	Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. <i>CMAJ Open</i> , 2017, 5, E800-E807.	1.1	25
143	MENINGITIS. <i>Lancet, The</i> , 1993, 341, 530.	6.3	24
144	Glucomannan and risk of oesophageal obstruction.. <i>BMJ: British Medical Journal</i> , 1986, 292, 591-592.	2.4	23

#	ARTICLE	IF	CITATIONS
145	Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. <i>Australian Health Review</i> , 2009, 33, 192.	0.5	23
146	Effects of information framing on the intentions of family physicians to prescribe long-term hormone replacement therapy. <i>Journal of General Internal Medicine</i> , 1999, 14, 591-598.	1.3	22
147	Personal formularies. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 333-341.	0.8	22
148	Informatics: Make sense of health data. <i>Nature</i> , 2015, 527, 31-32.	13.7	22
149	Adverse drug reactions: Can consumers provide early warning?. <i>Pharmacoepidemiology and Drug Safety</i> , 1994, 3, 257-264.	0.9	21
150	Big Data and Population Health. <i>Epidemiology</i> , 2017, 28, 759-762.	1.2	21
151	Ties That Bind. <i>Archives of Internal Medicine</i> , 2005, 165, 2493.	4.3	20
152	Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. <i>Globalization and Health</i> , 2005, 1, 15.	2.4	20
153	Attitudes of physicians and public to pharmaceutical industry "gifts". <i>Internal Medicine Journal</i> , 2010, 40, 335-341.	0.5	20
154	Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion. <i>The Cochrane Library</i> , 2011, , CD004172.	1.5	20
155	Specialist or generalist care? A study of the impact of a selective admitting policy for patients with cardiac failure. <i>International Journal for Quality in Health Care</i> , 2000, 12, 339-345.	0.9	19
156	Pharmaceutical policies: effects on rational drug use. <i>The Cochrane Library</i> , 2006, , .	1.5	19
157	Liberating the data from clinical trials. <i>BMJ, The</i> , 2015, 351, h4601.	3.0	19
158	The free trade agreement between Australia and the United States. <i>BMJ: British Medical Journal</i> , 2004, 328, 1271-1272.	2.4	18
159	Using Linked Health Administrative Data to Assess the Clinical and Healthcare System Impact of Chronic Diseases in Ontario. <i>Healthcare Quarterly</i> , 2011, 14, 23-27.	0.7	18
160	DEFECTIVE ABSORPTION OF INJECTED INSULIN. <i>Lancet, The</i> , 1978, 312, 741-742.	6.3	17
161	Agreement between two measures of drug use in a low-prevalence population. <i>Addictive Behaviors</i> , 1991, 16, 507-516.	1.7	17
162	NSAIDs and risk of upper gastrointestinal bleeding. <i>Lancet, The</i> , 1991, 337, 730-731.	6.3	17

#	ARTICLE	IF	CITATIONS
163	Factors influencing the uptake of technologies to minimize perioperative allogeneic blood transfusion: an interview study of national and institutional stakeholders. <i>Internal Medicine Journal</i> , 2001, 31, 230-236.	0.5	17
164	Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. <i>Medical Journal of Australia</i> , 2007, 187, 236-239.	0.8	17
165	What do health care professionals know about childhood asthma?. <i>Journal of Paediatrics and Child Health</i> , 1993, 29, 32-35.	0.4	16
166	Recent trends in the prescribing of cholesterol lowering drugs in Australia A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. <i>Medical Journal of Australia</i> , 1991, 155, 332-336.	0.8	15
167	Limitations of Health Insurance Commission (HIC) data for deriving prescribing indicators. <i>Medical Journal of Australia</i> , 2002, 176, 419-424.	0.8	15
168	Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. <i>Internal Medicine Journal</i> , 2005, 35, 206-210.	0.5	15
169	Blood transfusion and autologous donation: a survey of post-surgical patients, interest group members and the public. <i>Transfusion Medicine</i> , 2005, 15, 19-32.	0.5	15
170	The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high?. <i>Australian Health Review</i> , 2013, 37, 32.	0.5	15
171	Regional variation of premature mortality in Ontario, Canada: a spatial analysis. <i>Population Health Metrics</i> , 2019, 17, 9.	1.3	15
172	The Canadian Network for Observational Drug Effect Studies (CNODES): Reflections on the first eight years, and a look to the future. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 103-107.	0.9	15
173	Australian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in Australia. <i>Journal of Public Health Policy</i> , 2008, 29, 106-120.	1.0	14
174	Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1716-1722.	2.2	14
175	Population risk and burden of health behavioral-related all-cause, premature, and amenable deaths in Ontario, Canada: Canadian Community Health Survey-linked mortality files. <i>Annals of Epidemiology</i> , 2019, 32, 49-57.e3.	0.9	14
176	Health Systems and Sustainability: Doctors and Consumers Differ on Threats and Solutions. <i>PLoS ONE</i> , 2011, 6, e19222.	1.1	14
177	Patterns of analgesic and anti-inflammatory medicine use by Australian veterans. <i>Internal Medicine Journal</i> , 2007, 37, 798-805.	0.5	13
178	Achieving the World Health Organization's vision for clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 223-227.	1.1	13
179	Impact of restricting diagnostic imaging reimbursement for uncomplicated low back pain in Ontario: a population-based interrupted time series analysis. <i>CMAJ Open</i> , 2017, 5, E760-E767.	1.1	13
180	Characterising violent deaths of undetermined intent: a population-based study, 1999-2012. <i>Injury Prevention</i> , 2018, 24, 424-430.	1.2	13

#	ARTICLE	IF	CITATIONS
181	Flucloxacillin and cholestatic hepatitis. <i>Medical Journal of Australia</i> , 1994, 160, 525-525.	0.8	13
182	The Australian Guidelines for Subsidisation of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1992, 2, 422-426.	1.7	12
183	A population-based study of homicide deaths in Ontario, Canada using linked death records. <i>International Journal for Equity in Health</i> , 2017, 16, 133.	1.5	12
184	Unlocking First Nations health information through data linkage. <i>International Journal of Population Data Science</i> , 2018, 3, 450.	0.1	12
185	CHANGING TRENDS IN PERFORATED PEPTIC ULCER DURING THE PAST 45 YEARS. <i>ANZ Journal of Surgery</i> , 1992, 62, 729-732.	0.3	11
186	PERFORATED PEPTIC ULCER IN THE HUNTER REGION: A REVIEW OF 174 CASES. <i>ANZ Journal of Surgery</i> , 1992, 62, 338-343.	0.3	11
187	The PBS community awareness campaign: how helpful is blaming patients?. <i>Medical Journal of Australia</i> , 2003, 179, 544-545.	0.8	11
188	Ensuring the safety of new medications and devices: are naltrexone implants safe?. <i>Medical Journal of Australia</i> , 2008, 188, 438-439.	0.8	11
189	Access to routinely collected data for population health research: experiences in Canada and Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2018, 42, 430-433.	0.8	11
190	Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13345.	1.2	11
191	Meta-Analysis Workshop in Upper Gastrointestinal Hemorrhage. <i>Gastroenterology</i> , 1991, 100, 1481-1482.	0.6	10
192	What Drives Health-Care Spending Priorities? An International Survey of Health-Care Professionals. <i>PLoS Medicine</i> , 2007, 4, e94.	3.9	10
193	How do trainee doctors learn about research? Content analysis of Australian specialist colleges' intended research curricula. <i>BMJ Open</i> , 2020, 10, e034962.	0.8	10
194	Asthma and Chronic Obstructive Pulmonary Disease (COPD) Prevalence and Health Services Use in Ontario M <sup>A</sup> Ontis: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2014, 9, e95899.	1.1	10
195	The changing pattern of toxicity of digoxin. <i>Postgraduate Medical Journal</i> , 1981, 57, 358-362.	0.9	9
196	Renal and cardiovascular toxicity of non-steroidal anti-inflammatory drugs. <i>Inflammopharmacology</i> , 2000, 8, 1-18.	1.9	9
197	Changes to the Pharmaceutical Benefits Advisory Committee. <i>Medical Journal of Australia</i> , 2001, 174, 209-210.	0.8	9
198	Promoting quality use of medicines in South-East Asia: reports from country situational analyses. <i>BMC Health Services Research</i> , 2018, 18, 526.	0.9	9

#	ARTICLE	IF	CITATIONS
199	Fatal agranulocytosis attributed to co-trimoxazole therapy.. BMJ: British Medical Journal, 1977, 2, 316-316.	2.4	8
200	Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence-the Australian experience. British Journal of Clinical Pharmacology, 1997, 44, 421-425.	1.1	8
201	Cost-Effectiveness Analysis in the Treatment of Hypertension: A Medical View. Clinical and Experimental Hypertension, 1999, 21, 999-1008.	0.5	8
202	IQWiG methods â€“ a response to two critiques. Health Economics (United Kingdom), 2010, 19, 1137-1138.	0.8	8
203	Doctors and Drug Companies: Still Cozy after All These Years. PLoS Medicine, 2010, 7, e1000359.	3.9	8
204	What the public learns about screening and diagnostic tests through the media. Medical Journal of Australia, 2012, 197, 324-326.	0.8	8
205	Jaundice during cyproheptadine treatment.. BMJ: British Medical Journal, 1978, 1, 753-753.	2.4	7
206	Durable efficacy of metformin/glibenclamide* combination tablets (GlucovanceÂ®) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy. International Journal of Clinical Practice, 2004, 58, 820-826.	0.8	7
207	Gifts, Drug Samples, and other Items Given to Medical Specialists by Pharmaceutical Companies. Journal of Bioethical Inquiry, 2006, 3, 139-148.	0.9	7
208	How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns: Table 1.. Journal of Rheumatology, 2009, 36, 2114-2121.	1.0	7
209	Public Payments to Physicians in Ontario Adjusted for Overhead Costs. Healthcare Policy, 2012, 8, 30-36.	0.3	7
210	Walking the Path Together: Indigenous Health Data at ICES. Healthcare Quarterly (Toronto, Ont ), 2018, 20, 6-9.	0.3	7
211	Identifying the most effective essential medicines policies for quality use of medicines: A replicability study using three World Health Organisation data-sets. PLoS ONE, 2020, 15, e0228201.	1.1	7
212	Severe hypokalemia in hospitalized patients. Archives of Internal Medicine, 1979, 139, 978-980.	4.3	7
213	Acute respiratory failure and CNS-depressing drugs.. Postgraduate Medical Journal, 1981, 57, 279-282.	0.9	6
214	INHIBITION OF DRUG METABOLISM BY OMEPRAZOLE. Lancet, The, 1984, 324, 46-47.	6.3	6
215	OMEPRazole: EFFECTS ON OXIDATIVE DRUG METABOLISM IN THE RAT. Clinical and Experimental Pharmacology and Physiology, 1986, 13, 377-381.	0.9	6
216	Implications of the Australian Guidelines for the United States. Health Affairs, 1992, 11, 202-206.	2.5	6

#	ARTICLE	IF	CITATIONS
217	Assessing new health technologies: lessons to be learned from drugs. Medical Journal of Australia, 1999, 171, 554-556.	0.8	6
218	Published pharmaco-economic analyses: science or marketing?. Internal Medicine Journal, 2003, 33, 403-404.	0.5	6
219	Observations from the OMERACT Drug Safety Summit, May 2008. Journal of Rheumatology, 2009, 36, 2110-2113.	1.0	6
220	Deconstructing cancer: what makes a good quality news story?. Medical Journal of Australia, 2010, 193, 702-706.	0.8	6
221	The risk of coronary thrombosis with cyclooxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclooxygenase-2 gene. British Journal of Clinical Pharmacology, 2011, 72, 707-714.	1.1	6
222	Trends and uptake of new formulations of controlled-release oxycodone in Canada. Pharmacoepidemiology and Drug Safety, 2018, 27, 520-525.	0.9	6
223	Repeat testing for SARS-CoV-2: persistence of viral RNA is common, and clearance is slower in older people. Medical Journal of Australia, 2021, 214, 468-470.	0.8	6
224	Aging in Ontario: Using Population-Based Data in the Evaluation of Trends in Health System Use. Healthcare Quarterly, 2011, 14, 21-25.	0.7	6
225	New drugs for peptic ulcer. Medical Journal of Australia, 1984, 141, 303-308.	0.8	6
226	Drugs as a cause of gastrointestinal disease. Bailliere's Clinical Gastroenterology, 1994, 8, 271-300.	0.9	5
227	Pharmacoeconomics and policy decisions: The Australian health care system. Clinical Therapeutics, 1999, 21, 909-915.	1.1	5
228	Recent changes in the profile of prescription NSAID use in Australia. Medical Journal of Australia, 2000, 172, 188-188.	0.8	5
229	Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion. , 2003, , CD004172.		5
230	Misleading drug promotion?no sign of improvements. Pharmacoepidemiology and Drug Safety, 2004, 13, 797-799.	0.9	5
231	Pharmaceutical benefits scheme policy: confused and tough on patients. Internal Medicine Journal, 2006, 36, 211-213.	0.5	5
232	Meta-analysis of risk of gastrointestinal complications with NSAIDs. BMJ: British Medical Journal, 1997, 314, 445-445.	2.4	5
233	Burden of health behaviours and socioeconomic position on health care expenditure in Ontario. F1000Research, 2019, 8, 303.	0.8	5
234	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. PLoS ONE, 2022, 17, e0269482.	1.1	5

#	ARTICLE	IF	CITATIONS
235	Meta-analysisâ€”its role in assessing drug safety. , 1999, 8, 167-168.		4
236	The pharmaceutical industry and disease mongering. BMJ: British Medical Journal, 2002, 325, 216-216.	2.4	4
237	Supervisory fault tolerant control via common lyapunov function approach. , 2010, , .		4
238	Prescription medicines: decisionâ€™making preferences of patients who receive different levels of public subsidy. Health Expectations, 2014, 17, 15-26.	1.1	4
239	Retrospective analysis of trends in dispensing long-acting non-tamper-resistant oxycodone near the Canada-United States border. CMAJ Open, 2015, 3, E231-E235.	1.1	4
240	Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data. BMJ Open, 2017, 7, e013770.	0.8	4
241	Epidemiological Assessment of the Association Between NSAIDs and Peptic Ulcer Complications. , 1988, 24, 85-94.		4
242	Burden of health behaviours and socioeconomic position on health care expenditure in Ontario. F1000Research, 2019, 8, 303.	0.8	4
243	EARLY EXPERIENCE WITH A VERTICAL SPINNING-DISC NEBULISER. Lancet, The, 1981, 318, 664-666.	6.3	3
244	L-643.441: an H2-receptor antagonist with potent and long-lasting effects in man.. British Journal of Clinical Pharmacology, 1985, 20, 133-136.	1.1	3
245	ENZYME INDUCTION BY EATING CHARCOAL-GRILLED STEAK WITH NO EFFECT ON BLOOD LIPIDS. Clinical and Experimental Pharmacology and Physiology, 1989, 16, 783-788.	0.9	3
246	Pharmacoepidemiology as a focus for clinical epidemiology in developing countries. Journal of Clinical Epidemiology, 1991, 45, 101-105.	2.4	3
247	Should Indirect Costs and Benefits be Included?. Pharmacoeconomics, 1992, 1, 462-462.	1.7	3
248	GASTROINTESTINAL HAEMORRHAGE. Lancet, The, 1993, 341, 527-528.	6.3	3
249	Drug advertising: truths, halfâ€™truths and few statistics. Medical Journal of Australia, 2002, 177, 285-286.	0.8	3
250	Agreement between randomized and non-randomized studies: the effects of bias and confounding. BMC News and Views, 2001, 1, .	0.0	3
251	Editorial: Prescribing costs: whose responsibility?. Australian Prescriber, 1997, 20, 26-27.	0.5	3
252	Effectiveness of <scp>COVID</scp> â€”19 vaccines: findings from realâ€™world studies. Medical Journal of Australia, 2022, 216, 431-431.	0.8	3

#	ARTICLE	IF	CITATIONS
253	Failure of 2 h [14C]â€aminopyrine breath test to demonstrate microsomal enzyme induction by glutethimide [proceedings]. British Journal of Clinical Pharmacology, 1978, 6, 460P.	1.1	2
254	Indomethacin and perforated duodenal ulcer.. BMJ: British Medical Journal, 1980, 280, 1088-1089.	2.4	2
255	Effects of prior use of non-steroidal anti-inflammatory drugs on renal function and transfusion requirements after upper gastrointestinal haemorrhage. European Journal of Clinical Pharmacology, 1992, 43, 341-345.	0.8	2
256	Toxicity of dothiepin in overdose. Lancet, The, 1994, 343, 735.	6.3	2
257	Cost-effectiveness and Resource Allocationâ€Reply. JAMA - Journal of the American Medical Association, 2006, 295, 2723.	3.8	2
258	Sliding Mode Observers for Fault Estimation in Multisensor Avionics Systems. , 2015, , 323-341.		2
259	Commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs. International Journal of Epidemiology, 2018, 47, 362-367.	0.9	2
260	Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies. , 0, , 37-57.		2
261	Assessing the Impact of the Australia-United States Free Trade Agreement (AUSFTA) on Australian and Global Medicines Policy. SSRN Electronic Journal, 0, , .	0.4	2
262	Drug Information Centres: New Role for Pharmacists?. Scottish Medical Journal, 1977, 22, 147-150.	0.7	1
263	Drug therapy reviews: Intravenous fluid therapy. American Journal of Health-System Pharmacy, 1977, 34, 1332-1338.	0.5	1
264	ARGON LASER PHOTOCOAGULATION IN BLEEDING PEPTIC ULCERS. Lancet, The, 1982, 319, 99.	6.3	1
265	Cimetidine and Tranexamic Acid for Upper-Gastrointestinal-Tract Bleeding. New England Journal of Medicine, 1983, 309, 1328-1328.	13.9	1
266	Peptic ulcer and piroxicam. BMJ: British Medical Journal, 1985, 290, 1663-1664.	2.4	1
267	Monitoring the safety of over the counter drugs.. BMJ: British Medical Journal, 1987, 295, 1414-1414.	2.4	1
268	Potential for Bias in Economic Analyses. New England Journal of Medicine, 1991, 325, 1384-1385.	13.9	1
269	National Medicinal Drug Policies: their Relationship to Pharmacoepidemiology. , 0, , 433-447.		1
270	Patent law. Lancet, The, 2003, 361, 1059.	6.3	1



#	ARTICLE	IF	CITATIONS
271	Cyclooxygenase Inhibitors and Cardiovascular Riskâ€”Reply. JAMA - Journal of the American Medical Association, 2007, 297, 586.	3.8	1
272	Male-biased infant sex ratios and patterns of induced abortion. Cmaj, 2016, 188, 640-641.	0.9	1
273	Building a Systematic Online Living Evidence Summary of COVID-19 Research. Journal of the European Association for Health Information and Libraries, 2021, 17, 21-26.	0.2	1
274	An Active Fault-Tolerant Flight Control Strategy. Advances in Industrial Control, 2014, , 119-149.	0.4	1
275	Association between the regional variation in premature mortality and immigration in Ontario, Canada. Canadian Journal of Public Health, 2020, 111, 322-332.	1.1	1
276	The likely impact on drug regulation in Australia. Medical Journal of Australia, 1986, 144, 256-258.	0.8	1
277	Adverse reactions to Nâ€acetylcysteine. Medical Journal of Australia, 1989, 151, 300-302.	0.8	1
278	Frequency and pattern of radionuclide administration to medical patients in a general hospital. European Journal of Nuclear Medicine and Molecular Imaging, 1977, 2, 133-5.	2.2	0
279	Rational choice of drugs for ulcer therapy. Medical Journal of Australia, 1984, 141, 726-727.	0.8	0
280	Endoscopic Coagulation for Gastrointestinal Bleeding. New England Journal of Medicine, 1988, 318, 185-188.	13.9	0
281	Trial of streptokinase in ischaemic stroke. Lancet, The, 1995, 345, 1053.	6.3	0
282	â€œPharmaceutical securityâ€: a new research agenda. Medical Journal of Australia, 1998, 169, 262-263.	0.8	0
283	Pharmacists' outreach visits and doctors' prescribing. Medical Journal of Australia, 1999, 170, 460-461.	0.8	0
284	Bridges to Iran. Lancet, The, 2003, 361, 438.	6.3	0
285	Effect of computerised prescribing on use of antibiotics. Medical Journal of Australia, 2003, 179, 62-63.	0.8	0
286	Systematic review of autologous transfusion techniques. Transfusion Medicine, 2005, 15, 255-255.	0.5	0
287	Medical Research and the News Media. New England Journal of Medicine, 2005, 352, 838-839.	13.9	0
288	Global Pharmaceuticals: Ethics, Markets, Practices. Australian and New Zealand Journal of Public Health, 2007, 31, 91-92.	0.8	0

#	ARTICLE	IF	CITATIONS
289	COX-2, NSAIDs, and cardiovascular risk. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 296-302.	0.8	0
290	Aspirin use in children: heeding the warning?. <i>Australian Journal of Public Health</i> , 2010, 16, 35-37.	0.2	0
291	Doctors and drug companies: Still cozy after all these years. <i>International Journal of Risk and Safety in Medicine</i> , 2011, 23, 7-10.	0.3	0
292	SUPERVISORY FAULT TOLERANT CONTROL BASED ON DWELL-TIME CONDITIONS. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2011, 44, 13717-13722.	0.4	0
293	Response to authors re commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs. <i>International Journal of Epidemiology</i> , 2018, 47, 675-676.	0.9	0
294	A FTC Strategy for Safe Recovery against Trimmable Horizontal Stabilizer Failure with Guaranteed Nominal Performance. <i>Lecture Notes in Control and Information Sciences</i> , 2010, , 337-361.	0.6	0
295	What are the Roles and Responsibilities of the Media in Disseminating Health Information?. , 2011, , 197-213.		0
296	Review and Basic Concepts. <i>Advances in Industrial Control</i> , 2014, , 5-27.	0.4	0
297	Regional Inequalities in All-Cause and Premature Mortality in Ontario. <i>HealthcarePapers</i> , 2018, 17, 28-34.	0.2	0
298	NSAIDs as a Cause of Morbidity and Mortality from Peptic Ulcer Complications in New South Wales. , 2018, , 255-260.		0
299	Do patients understand asthma?. <i>Medical Journal of Australia</i> , 1989, 150, 226-226.	0.8	0
300	Antihypertensive drugs and COVID-19. <i>Heart</i> , 2021, 107, 85.1-85.	1.2	0
301	Title is missing!. , 2020, 15, e0228201.		0
302	Title is missing!. , 2020, 15, e0228201.		0
303	Title is missing!. , 2020, 15, e0228201.		0
304	Title is missing!. , 2020, 15, e0228201.		0
305	National Medicinal Drug Policies: Their Relationship to Pharmacoepidemiology. , 0, , 375-390.		0